общий прогноз заболевания и способность к излечению.
3. Механизмы до конца не изучены, но основными факторами взаимосвязи ожирения с раковым процессом считаются: инсулиновая «нечувствительность», увеличение концентрации лептина и инсулиноподобного фактора роста, снижение концентрации адипонектина, изменение баланса половых гормонов и процесс хронического воспаления.
4. Микрофлора кишечника приобретает все большее значение в изучении механизмов предотвращения ракового процесса. Известно, что правильный баланс кишечных бактерий с преобладанием Lactobacillus способен тормозить развитие и рост раковых клеток. Наш образ питания является основным фактором, влияющим на композицию микрофлоры кишечника, создавая «полезный» или «вредный» варианты.
Список литературы (глава 1)
1. AR Carmichael, Obesity as a risk factor for development and poor prognosis of breast cancer, An International Journal of Obstetrics&Gynaecology, volume 113, Issue 10, pages 1160–1166
2. La Vecchia C, Negri E, Franceschi S, Talamini R, Bruzzi P, Palli D, et al., Body mass index and post-menopausal breast cancer: an age-specific analysis, Br J Cancer 1997; 75: 441–4.
3. Petrelli JM, Calle EE, Rodriguez C, Thun MJ.,Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 2002; 13: 325—32.
4. Lahmann PH, Lissner L, Berglund G. Breast cancer risk in overweight postmenopausal women, Cancer Epidemiol Biomarkers Prev 2004; 13: 1414.
5. Chlebowski RT, Aiello E, McTiernan A. “Weight loss in breast cancer patient management” J Clin Oncol 2002;20: 1128—43.
6. Enger SM, Greif JM, Polikoff J, Press M. Body weight correlates with mortality in early-stage breast cancer. Arch Surg 2004; 139: 954—8.
7. McTiernan A, Rajan KB, Tworoger SS, Irwin M, Bernstein L, Baumgartner R, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003; 21: 1961—6.
8. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer 2003;45:1–16.
9. Stoll BA. Nutrition and breast cancer risk: can an effect via insulin resistance be demonstrated? Breast Cancer Res Treat 1996; 38: 239–46.
10. Bruning PF. Endogenous estrogens and breast cancer a possible relationship between body fat distribution and estrogen availability. J Steroid Biochem 1987; 27: 487–92.
11. Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer Gut 2013; 62: 6 933–947
12. Akiyoshi T, Ueno M, Fukunaga Y, et al. Effect of body mass index on short-term outcomes of patients undergoing laparoscopic resection for colorectal cancer: a single institution experience in Japan. Surg Laparosc Endosc Percutan Tech 2011; 21: 409–14.
13. Singh A, Muthukumarasamy G, Pawa N, et al. Laparoscopic colorectal cancer surgery in obese patients. Colorectal Dis 2011; 13: 878–83.
14. Simkens LH, Koopman M, Mol L, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer 2011; 47: 2560–7.
15. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007;86: s 836–42.
16. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127–37.
17. Donohoe CL, Doyle SL, Reynolds JV. Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 2011; 3: 12.
18. Pearson JR, Gill CI, Rowland IR. Diet, fecal water, and colon cancer— development of a biomarker. Nutr Rev 2009; 67: 509–26.
19. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer. 1995 Jul-Aug; 31A(7–8): 1067–70.
20. Everson GT, McKinley C, Kern F Jr. Mechanisms of gallstone formation in women. Effects of exogenous estrogen (Premarin) and dietary cholesterol on hepatic lipid metabolism. J Clin Invest 1991; 87: 237–46.
21. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011; 140: 1807–16.
22. Cani PD, Osto M, Geurts L, et al. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279–88.
23. DiBaise JK, Zhang H, Crowell MD, et al. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc 2008; 83: 460–9.
25. Ildaphonse G, George PS, Mathew A., Obesity and kidney cancer risk in men: a meta-analysis. Asian Pac J Cancer Prev. 2009 Apr-Jun; 10(2): 279–86.
26. Bergström A1, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer – a quantitative review. Br J Cancer. 2001 Sep 28;85(7):984-90.
27. Gui-Ming Zhang, Yao Zhu and Ding-Wei Ye. Metabolic syndrome and renal cell carcinoma.World J Surg Oncol. 2014 Jul 29; 12(1): 236.
28. Häggström C, Rapp K, Stocks T, Manjer J, Bjørge T, Ulmer H, Engeland A, Almqvist M, Concin H, Selmer R, Ljungberg B, Tretli S, Nagel G, Hallmans G, Jonsson H, Stattin P. Metabolic factors associated with risk of renal cell carcinoma. PLoS One. 2013;8(2):e57475.
29. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE, Obesity and cancer-mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014 Aug; 10(8): 455–65.
30. Otunctemur A, Ozbek E, Sahin S, Dursun M, Besiroglu H, Koklu I, Erkoc M, Danis E, Bozkurt M, Gurbuz A. Diabetes mellitus as a risk factor for high grade renal cell carcinoma. Asian Pac J Cancer Prev. 2014; 15(9): 3993–6.
31. De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013; 2013: 291546. doi: 10.1155/2013/291546. Epub 2013 Aug 29.
32. Bollschweiler E, Wolfgarten E, Gutschow C, et al. Demographic variations in the rising incidence of esophageal adenocarcinoma